Kosan Biosciences

Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors

Retrieved on: 
Thursday, September 1, 2022
University, Gilead, Bristol Myers Squibb, Research, NASDAQ, ATTR, Board, AL, Executive, Senior, NGM, Kosan Biosciences, MBA, GLOBE, Partner, Leadership, Chiron Corporation, Biology, Board of directors, Biotechnology, Therapy, Neurodegeneration, Company, Chemical engineering, LLC, Business, Kite Pharma, Director, Chicago (franchise), Industry, Acquisition, Management, Northwestern University

With the appointment of Ms. Kim, Prothena will expand its Board to 10 directors.

Key Points: 
  • With the appointment of Ms. Kim, Prothena will expand its Board to 10 directors.
  • We welcome Ms. Kim to our Board and look forward to her many contributions.
  • After watching the strong execution of Prothena over the past years, Im excited to join the Board of Directors at this pivotal stage for the company.
  • Ms. Kim currently serves on the Board of Directors for A2 Biotherapeutics, Inc., ReCode Therapeutics, Inc., IconOVir Bio, Inc., Aktis Oncology, PACT Pharma, Protego Therapeutics, and InduPro Labs.

AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program

Retrieved on: 
Friday, January 7, 2022
Harvard Business School, Therapy, View, University, CALA, Research, Company, Controller, Patient, Eli Lilly and Company, Education, Kosan Biosciences, State, Infection, NTM, Chief diversity officer, Lilly, CEO, NASDAQ, Berkeley, Economic development, Accounting, AN2, Board, Eli Lilly, Board of directors, Drug development, Multimedia, Business administration, Certified Public Accountant, Pharmaceutical industry, Management, Indiana University, Finance, Citadel

AN2 successfully completed an oversubscribed $80 million Series B redeemable convertible preferred stock financing in March 2021.

Key Points: 
  • AN2 successfully completed an oversubscribed $80 million Series B redeemable convertible preferred stock financing in March 2021.
  • The financing is expected to support advancement of AN2's development candidate epetraborole, a once-daily, orally administered investigational treatment for patients with chronic non-tuberculous mycobacterial lung disease (NTM).
  • In addition, AN2 Therapeutics also appointed two additional members to its Board of Directors, Patricia Martin and Stephanie Wong.
  • AN2 is developing epetraborole, a once-daily oral investigational treatment for patients with chronic non-tuberculous mycobacterial lung disease (NTM).For more information, visit www.an2therapeutics.com .

ChemoCentryx Announces Appointment of Susan M. Kanaya to Board of Directors

Retrieved on: 
Monday, March 8, 2021
Kosan Biosciences, Vice president

MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Companys Executive Vice President and Chief Financial and Administrative Officer, to the ChemoCentryx Board of Directors effective March 2, 2021.

Key Points: 
  • MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Companys Executive Vice President and Chief Financial and Administrative Officer, to the ChemoCentryx Board of Directors effective March 2, 2021.
  • Susan Kanayas many fundamental contributions have been key to ChemoCentryxs growth and prosperity, said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx.
  • To all of this, we now have the great fortune of adding Susans many strengths to our Board.
  • Before joining ChemoCentryx, Ms. Kanaya was the Senior Vice President, Finance, and Chief Financial Officer at Kosan Biosciences Inc., from 1999 to 2005.